http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2055309-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_666d69a0b9503881fd0bacaeb7b4e489 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-20 |
| filingDate | 2007-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80d0dfa40f813d809f3b31521b19aa06 |
| publicationDate | 2009-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2055309-A1 |
| titleOfInvention | Vancomycin and Teicoplanin anhydrous formulations for topical use |
| abstract | The invention concerns pharmaceutical anhydrous formulation for topical use comprising Vancomycin, Vancomycin Hydrochloride, or Teicoplanin, and Dimethylsulfoxide. n In a preferred embodiment the formulation further comprises one or more glycols and/or ethers thereof, and optionally one or more fatty acids triglycerides and/or the polyoxyethylene derivative thereof. n The use of Dimethylsulfoxide in anhydrous formulation for topical use leads to formulations characterized by high homogeneity and high concentration, if desired, of Vancomycin, Vancomycin Hydrochloride, or Teicoplanin. These Dimethylsulfoxide-containing formulations are also very stable in time. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2629779-A4 |
| priorityDate | 2007-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.